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Abstract: The broad aim of this work was to investigate and
optimize the properties of calcium phosphate bone cements
(CPCs) for use in vertebroplasty to achieve effective primary
fixation of spinal fractures. The incorporation of collagen, both
bovine and from a marine sponge (Chondrosia reniformis),
into a CPC was investigated. The biological properties of the
CPC and collagen–CPC composites were assessed in vitro
through the use of human bone marrow stromal cells. Cytotox-
icity, proliferation, and osteoblastic differentiation were eval-
uated using lactate dehydrogenase, PicoGreen, and alkaline
phosphatase activity assays, respectively. The addition of both
types of collagen resulted in an increase in cytotoxicity, albeit
not to a clinically relevant level. Cellular proliferation after 1, 7,
and 14 days was unchanged. The osteogenic potential of the
CPC was reduced through the addition of bovine collagen but
remained unchanged in the case of the marine collagen. These
findings, coupled with previous work showing that incorpora-
tion of marine collagen in this way can improve the physical
properties of CPCs, suggest that such a composite may offer
an alternative to CPCs in applications where low setting times
and higher mechanical stability are important. VC 2015 The
Authors. Journal of Biomedical Materials Research Part B: Applied
Biomaterials Published by Wiley Periodicals, Inc. 00B: 000–000, 2015.
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INTRODUCTION
Fractures of the spine and neck result in over 13,000
annual emergency admissions to hospital in England alone,1
with burst fractures accounting for around 15%.2 Conserva-
tive treatments like bed rest, external bracing and analgesics
have been typically used to treat such fractures; however,
such treatments are considered by many to be inadequate
and are commonly being replaced by minimally invasive
surgical procedures.3
An example of such a procedure is vertebroplasty—an
image-guided therapy that involves the injection of cement
into the vertebral body. It has become a widely used treat-
ment for osteoporotic compression fractures, with up to
84% of patients in some studies experiencing rapid and
profound pain relief as well as an increase in functional
activities.4 Despite this, research into the use of vertebro-
plasty for the treatment of more severe fractures has been
limited and is yet to be realized in a clinical setting.
Poly(methyl methacrylate) (PMMA) is the current
cement of choice in vertebroplasty, partly because of its
excellent biocompatibility and hemocompatibility.5 However,
some concerns have been raised regarding its use, such as
the high polymerization temperatures, monomer cytotoxic-
ity, and an increased risk of fracture in adjacent vertebral
bodies.6 Bioactivity can be used to induce positive
responses in vivo, leading to an interest in calcium phos-
phate bone cements (CPCs) for this application. CPCs mimic
the natural mineral phase of bone and are potentially
resorbable, consequently promoting natural bone remodel-
ing and bone ingrowth. CPCs have the potential to be partic-
ularly effective in the treatment of burst fractures. The
typical mechanisms of injury for such fractures are road
trafﬁc accidents and falls from height,7 meaning that burst
fractures usually occur in the younger population who, in
general, have a greater capacity for bone remodeling.8 How-
ever, concerns remain regarding the use of CPCs in the
treatment of burst fractures because of shortcomings in
their mechanical properties.9–11
Approximately 30%–35% of the dry weight of bone is
organic material, and of this, around 95% is type I
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collagen.12 This collagen plays an important role in bone
function and formation, and use of collagen as a biomaterial
was investigated as early as the 1970s.13 Collagen has been
used directly as a biomaterial, in the form of hydrogels, as
an additive to calcium phosphate scaffolds, and as an addi-
tive to CPCs. It is evident from such work that collagen has
the potential to be of signiﬁcant use in the ﬁeld of bone
regeneration because it has excellent biocompatibility and
low antigenicity.14 As such, in addition to improving
mechanical properties, it is hypothesized that the incorpora-
tion of collagen will also result in biological beneﬁts. It has
been previously shown that incorporation of bovine collagen
into CPCs results in increased cellular adhesion in vitro15,16;
also, in vivo, Mai et al.17 demonstrated that a bovine colla-
gen–CPC composite was not only biocompatible but also
resorbable. Despite this, concerns regarding the clinical
safety of collagen remain an obstacle to its use in biomateri-
als. The clinical incidence of adverse reactions to collagen is
extremely rare; the incidence of these reactions is <3%, and
they can generally be resolved within a few months.18 A
much greater concern, particularly because cattle are the
primary source of collagen on a commercial scale,14 is the
risk of transmissible spongiform encephalopathies, such as
bovine spongiform encephalopathy. A safer option is to use
porcine-derived collagen, although it has been widely
reported that collagen from aquatic and particularly marine
sources could be even safer.14,19–22
A possible alternative source of collagen is the common
marine Demosponge Chondrosia reniformis Nardo, 184723).
It has been identiﬁed worldwide, has a high collagen con-
tent,24 and a low risk of detrimental toxic compounds.22
The fact that C. reniformis also reproduces asexually sug-
gests that harvesting of the sponge for collagen isolation
could be conducted on a commercial scale.25 Swatschek
et al.22 developed a method for isolating collagen from C.
reniformis and demonstrated its suitability as a substitute
for collagen from conventional sources. The collagen exhib-
its many features associated with mammalian collagen and,
in some aspects, has been shown to display signiﬁcant simi-
larities to bovine collagen.26,27
Such work suggests that using potentially safer collagen
from C. reniformis in place of bovine-derived collagen would
yield similar beneﬁts to those associated with the use of
bovine collagen.
Previous work has shown that a CPC formulated from a
powder phase of 100% a-tricalcium phosphate (a-TCP-CPC)
displayed superior physical properties to a CPC based on a
commercial formulation initially developed by Merck KGaA
(Merck-CPC),28 as well as meeting several of the clinical
requirements for vertebroplasty.29 When compared with
Merck-CPC, the compressive strength of a-TCP-CPC was
more than doubled from 15 to 32 MPa, and a near 70%
increase in Young’s modulus from 650 to 1100 MPa was
observed. These enhancements in mechanical properties
were coupled with a threefold improvement in injectability,
based on a method developed by Khairoun et al.,30 from
around 15% to over 50%. In addition, the incorporation of
1 wt % bovine collagen into Merck-CPC resulted in signiﬁ-
cant improvements in fracture toughness (p< 0.01) and
ﬁnal setting time (p< 0.001) without compromising com-
pressive strength, Young’s modulus, or injectability. It should
be noted, however, that injectability was reduced by around
a third.31 Furthermore, the incorporation of collagen from
the marine Demosponge C. reniformis (Nardo, 184723) has
also been shown to signiﬁcantly reduce both the initial and
ﬁnal setting times of a-TCP-CPC to within the clinical range
required for vertebroplasty without compromising its com-
pressive strength, Young’s modulus, or injectability.28,32–34
Based on these earlier investigations, the aim of this
study was to assess the in vitro biological response associ-
ated with collagen–CPC composites, from both bovine and
marine sponge origin, formulated from a-TCP-CPC.
MATERIALS AND METHODS
Cement production
a-TCP-CPC was formulated from a powder phase of 94%
a-TCP (produced in-house according to Jack et al.35) and a
liquid phase of 5 wt % Na2HPO4 in deionized water at a
liquid-to-powder ratio of 0.35 mL/g. The powder and liquid
components were mixed for 1 min, delivered into a polytet-
raﬂuoroethylene (PTFE) (RS Components, Northampton-
shire, UK) mold within 4 min, and then placed in an oven
held at 37 C for 20 min. The dimensions of the cement
samples produced from the PTFE mold were 2 mm in
height and 4 mm diameter. The PTFE mold containing the
cement was placed in a bath of Ringer’s solution for 5 days
at 37 C to ensure complete setting.
Collagen–CPC composites were produced using broadly
the same method as earlier. Bovine-derived collagen (Sigma-
Aldrich, Dorset, UK) and collagen extracted from C. renifor-
mis (KliniPharm GmbH, Frankfurt, Germany) were incorpo-
rated into a-TCP-CPC at a loading of 1 wt % to form
composites referred to as BC-CPC and MC-CPC, respectively.
Prior to incorporation into the powder phase of the cement,
the bovine ﬁbers were cryogenically ground using a Freezer
Mill 6850 (Rondol Technology, Staffordshire, UK) for two
cycles of 2 min, a method previously shown to reduce ﬁber
length.36 The dry powder components were turbo blended
at 16006 10 rpm for 1 min (DAC 150 FVZ Speed Mixer,
Hauschild & Co. KG, Hamm, Germany) to ensure thorough
mixing. The marine ﬁbers were suspended in the liquid
phase of the cement before mixing with the powder phase.
Two cement formulations were used as controls: Merck-
CPC and a PMMA-based cement. Merck-CPC was formulated
from a powder phase of 61% a-TCP, 26% calcium phos-
phate (CaHPO4), 10% calcium carbonate (CaCO3), and 3%
hydroxyapatite (Plasma Biotal, Derbyshire, UK) and a liquid
phase of 4 wt % di-sodium hydrogen phosphate (Na2HPO4)
(Fisher Scientiﬁc, Leicestershire, UK) in deionized water
mixed at a liquid-to-powder ratio of 0.35 mL/g. It is based
on a commercial formulation developed by Merck KGaA
(Darmstadt, Germany) to have a similar chemical composi-
tion and crystalline structure with that of the mineral phase
of bone.37 The PMMA cement used was Vertebroplastic
Radiopaque Resinous Material (DePuy, Leeds, UK), which is
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a commercially available cement routinely used clinically for
vertebroplasty (referred to herein as VP-PMMA).
Surface roughness (Ra) of each cement type was assessed
using a stylus proﬁlometer (Talysurf 4, Taylor Hobson,
Leicester, UK). All samples, barring VP-PMMA, which was
produced under aseptic conditions as per the manufacturer’s
instructions, were sterilized using g-irradiation in accordance
with ISO-11137-1:200638 (Isotron Applied Sterilisation Tech-
nologies, Synergy Health, Swindon, UK). Sterilization using g-
irradiation has been reported as the most suitable steriliza-
tion technique for collagen extracted from C. reniformis.39
In vitro evaluation
In vitro evaluation was carried out using human bone marrow
stromal cells (hBMSCs), which are primary cells similar to
those that would be in contact with the implant in vivo and
are capable of differentiating along the osteogenic lineage.40
Following informed patient consent, approximately 6 mL
of bone marrow was collected from the tibial medullary
canal of a 19-year-old male undergoing a tibial intramedul-
lary rod ﬁxation procedure at Belfast’s Royal Victoria Hospi-
tal. The sample was suspended 1:1 in sterile phosphate-
buffered saline (PBS). The resulting suspension was passed
through a 21-gauge needle several times to break up large
clumps of bone marrow, before the cells were washed and
resuspended in 8 mL of sterile PBS. The mononuclear cell
fraction was separated using density centrifugation with
Lymphoprep (Axis-Shield, Dundee, UK) at a speed of 600g
for 40 min. Separated cells were plated at a seeding density
of 1–3 3 105 cells/cm2 in minimum essential medium alpha
modiﬁcation with L-glutamine and without ribonucleosides
(Analab, Co., Antrim, UK) supplemented with a further 1%
L-glutamine (Gibco, Invitrogen, Paisley, UK), 1% penicillin–
streptomycin solution (Gibco), and 10% foetal bovine serum
(FBS GOLD, Analab). Cells were left undisturbed for 1 week
and fed twice weekly thereafter. When the cells had been
cultured to near conﬂuency, they were passaged using
0.25% trypsin/EDTA (Gibco) at a ratio of 1:4 to expand the
cell population.
Cement samples were placed in 96-well tissue culture
plates and seeded with hBMSCs at passage four (P4) at a
density of 5 3 104 cells/cm2. Outcome measures were cyto-
toxicity, determined by lactate dehydrogenase (LDH) assay;
proliferation, determined by PicoGreen assay; and differen-
tiation, determined by alkaline phosphatase (ALP) activity
assay. The LDH and PicoGreen assays were performed with
a CytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Prom-
ega, Madison, WI) and a Quant-iT PicoGreen dsDNA Reagent
and Kit (Molecular Probes, Invitrogen), respectively, in
accordance with the manufacturer’s instructions. The
amount of ALP present in the lysates was quantiﬁed
through the use of a standard curve, produced by adding
known amounts of p-nitrophenylphosphate to 0.1% Triton
X-100 in PBS. The assay buffer (1.5M alkaline buffer solu-
tion) was diluted 1:3 with dH2O. A 100-mg capsule of phos-
phatase substrate was dissolved in 100 mL of the assay
buffer (all from Sigma-Aldrich). Two hundred microliters of
substrate was added to 50 lL of cell lysates and standards
in a 96-well assay plate before being protected from light,
and incubated at 37 C for 30 min. The reaction was
stopped by adding 50 lL of 3M sodium hydroxide (Sigma-
Aldrich), and absorbance read at 405 nm (GENios Micro-
plate Reader). A PicoGreen assay was performed on the
same cell lysates to allow ALP activity to be normalized to
cell number.
Cytotoxicity was measured at day 1, and proliferation
measured at days 1, 7, and 14. At each time point, there were
ﬁve repeats of each formulation; four on which the assays
would be carried out and an additional one for scanning elec-
tron microscopy (SEM) analysis. Cement samples without cells
served as a negative control. All wells were ﬁlled with 200 lL
of complete medium, apart from the day 1 plate, which was
ﬁlled with phenol red-free Dulbecco’s modiﬁed Eagle medium
(Gibco) containing supplements as earlier. Cells were fed twice
weekly for the duration of the experiment.
Differentiation was measured at days 7, 14, and 21. Pico-
Green and ALP activity assays were performed at all three
time points to allow ALP activity to be normalized to cell
number. In addition to the wells containing samples, cells
were added to three empty wells, and all wells were ﬁlled
with 200 lL of complete medium. When the cells in the three
empty wells were near conﬂuency, complete medium was
replaced with osteogenic medium (complete medium with
additional supplements: 50 lM ascorbate-2-phosphate, 0.1
lM dexamethasone, and 10 lM b-glycerophosphate) (all
from Sigma-Aldrich). Cells were fed twice weekly with osteo-
genic medium for the duration of the experiment.
SEM was also used to qualitatively assess the biocompati-
bility of the cements at days 7 and 14. Cells were cultured as
described earlier, and specimens were ﬁxed and dried
through graded alcohols and hexamethyldisilazane (Sigma-
Aldrich) before being sputter coated with pure gold (Polaron
E5150, Polaron Instruments, Doylestown, PA) and viewed
using a JEOL JSM 840 (Jeol, Hertfordshire, UK) at an acceler-
ating voltage of 15 kV, and images recorded onto Ilford FP4
ﬁlm (Ilford Photo, Cheshire, UK) before being scanned.
Statistical analysis
One-way analysis of variance (ANOVA) was used to identify
signiﬁcant differences between cement formulations. Where
a signiﬁcant difference was indicated by ANOVA, pair-wise
comparisons to assess intergroup differences were carried
out using Tukey’s honestly signiﬁcant difference tests, pro-
vided the sample sizes were the same. If sample sizes were
not consistent (for example, due to lost or erroneous read-
ings) pair-wise comparisons were carried out using Gabri-
el’s procedure.
All statistical analyses herein were performed using
PASW Statistics 18.0 (IBM Corp., Armonk, NY). A p-value of
0.05 was considered signiﬁcant throughout.
RESULTS
Surface roughness
All cements had similar roughnesses, with the exception of
BC-CPC; the other formulations were 30%– 45% less
rough compared with BC-CPC (Figure 1).
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Cytotoxicity
The percentage cell death associated with all cement types was
relatively low (<15%) (Figure 2). The lowest percentage cell
death was observed on the a-TCP-CPC and the highest on BC-
CPC. ANOVA indicated that BC-CPC induced signiﬁcantly higher
cytotoxicity than all of the other cements, with the exception of
MC-CPC (p50.038, 0.009, and <0.001 when compared against
VP-PMMA, Merck-CPC, and a-TCP-CPC, respectively). Further,
a-TCP-CPC was also shown to induce signiﬁcantly less cytotox-
icity compared with MC-CPC (p50.022).
Scanning electron microscopy
SEM conﬁrmed cell attachment and qualitatively demon-
strated proliferation (Figure 3). All cement formulations
supported cell attachment and proliferation with many ﬁlo-
podia extending from cells to the cement surface and to
adjacent cells. Qualitatively, an increase in cell number was
observed over time. No clear distinction was evident
between the CaP-based formulations, although BC-CPC and
MC-CPC seemed to support cell growth equally well.
Proliferation
There was a general increase in cell number with time, indi-
cating that all cement formulations support cell proliferation (Figure 4). The amount of dsDNA more than doubled on all
cement formulations over the 14-day culture period. No sig-
niﬁcant differences between the cements were observed at
day 1 (p50.171). At day 7, there were signiﬁcantly more
cells on the VP-PMMA cement than on MC-CPC (p50.021),
but this was no longer evident at day 14. Instead, there was
now a signiﬁcantly higher cell number on a-TCP-CPC when
compared with Merck-CPC (p5 0.008).
Differentiation
Large increases in ALP activity were observed as the experi-
ment progressed (Figure 5). The largest increases were
seen between days 7 and 14, where increases in ALP activ-
ity of over 160% were observed on all cement formulations
and both Merck-CPC and BC-CPC, demonstrating increases
well in excess of 500%. This trend continued from day 14
to day 21, though the increases in ALP activity were less
marked, typically ranging from around 30% to 160%.
FIGURE 1. Surface roughness of samples (mean6 standard error;
n54 (n57 for VP-PMMA)).
FIGURE 2. Percentage of total cell death associated with each cement
type as assessed with an LDH assay at day 1 (cells seeded at P4;
mean6 standard error; n5 6 for all cement types except for a-TCP-
CPC where n5 5).
FIGURE 3. Cell growth on the cements at days 7 and 14.
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There was an effect of cement formulation on ALP activ-
ity. Cells cultured on VP-PMMA cement showed a lower ALP
activity when compared with the CaP-based formulations,
and this was statistically signiﬁcant at each of the time
points (Table I). Cells cultured on BC-CPC had a lower ALP
activity compared with that of the other CaP-based formula-
tions at all time points, and this was signiﬁcantly different
than the unaugmented a-TCP-CPC at days 7 (p50.046) and
21 (p50.002). Merck-CPC supported signiﬁcantly lower
ALP activity compared with that of a-TCP-CPC at day 7
(p50.038), but no signiﬁcant differences were observed at
the latter two time points.
DISCUSSION
The novel a-TCP-CPC, which has been optimized for its
mechanical and handling properties, was compared against
Merck-CPC, a relevant market comparator. In addition to
displaying superior physical properties, this study conﬁrms
that a-TCP-CPC maintains a similar level of biocompatibility
and bioactivity to Merck-CPC. No signiﬁcant difference in
cytotoxicity was observed while proliferation was signiﬁ-
cantly higher on a-TCP-CPC; beyond the ﬁrst time point, the
level of differentiation was also retained in the novel
formulation.
The percentage cell death (3%–7%) reported for the
unaugmented CPCs is in line with previously published data
for tissue culture plastic and lower than that reported for
other biomaterials commonly used in this ﬁeld, for example,
hydroxyapatite.41 The incorporation of collagen resulted in a
slight increase in cytotoxicity. This is in contrast to some
published work which suggests that incorporation of bovine
collagen into CPCs results in increased cellular adhe-
sion.15,16 Reasons for this difference are unclear; however,
differences in both CPC formulation and collagen handling,
in addition to cell type, may be responsible. The increased
cell death observed on BC-CPC may be a result of an
increased surface roughness, which has been shown to
lower surface adhesion of osteoblasts.42 This was not the
case with the MC-CPC, which has a surface roughness not
signiﬁcantly different to that of the a-TCP-CPC and VP-
PMMA cements because of the preparation methods.43
Therefore, a possible explanation for the slight increase in
cytotoxicity with this augmented cement is that, despite the
seemingly low risk of toxic compounds from C. reniformis as
an edible sponge,44 some detrimental compounds are
retained in the collagen after the extraction process.
Although extracts from the sponge had no signiﬁcant deter-
rent effects on ﬁsh45 and crabs,46 work by Sepcˇic´ et al.47
FIGURE 4. Cell number on the cements based on the amount of
dsDNA recorded following a PicoGreen assay (cells seeded at P4;
mean6 standard error; n55).
FIGURE 5. ALP activity per microgram dsDNA for all cement formula-
tions (cells seeded at P4; mean6 standard error; n5 5, apart from
Merck-CPC at day 14 where n5 4).
TABLE I. Statistical Analyses Comparing ALP Activity for All
Cement Types at Each Time Point as well as Each Time Point
for All Cement Types
Time Point Cement Comparison p-Value
Day 7 VP-PMMA Merck-CPC 0.015*
a-TCP-CPC <0.001*
BC-CPC 0.012*
MC-CPC <0.001*
Merck-CPC a-TCP-CPC 0.038*
BC-CPC >0.999
MC-CPC 0.144
a-TCP-CPC BC-CPC 0.046*
MC-CPC 0.958
BC-CPC MC-CPC 0.17
Day 14 VP-PMMA Merck-CPC <0.001*
a-TCP-CPC <0.001*
BC-CPC <0.001*
MC-CPC <0.001*
Merck-CPC a-TCP-CPC 0.999
BC-CPC 0.684
MC-CPC 0.876
a-TCP-CPC BC-CPC 0.243
MC-CPC 0.997
BC-CPC MC-CPC 0.059
Day 21 VP-PMMA Merck-CPC <0.001*
a-TCP-CPC <0.001*
BC-CPC <0.001*
MC-CPC <0.001*
Merck-CPC a-TCP-CPC 0.798
BC-CPC 0.02*
MC-CPC 0.96
a-TCP-CPC BC-CPC 0.002*
MC-CPC 0.408
BC-CPC MC-CPC 0.081
*Denotes a significant difference.
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has shown that an aqueous extract from C. reniformis homog-
enate displays some cytocidal activity as well as low haemo-
lytic activity. Despite this, the fact that both collagen-
augmented CPCs displayed a lower level of cytotoxicity than
is associated with other commonly used biomaterials sug-
gests that the level of cytotoxicity associated with the
collagen-augmented CPCs is not likely to be clinically relevant.
This was conﬁrmed by SEM analysis, which showed cells
adhering and adopting the ﬂattened and elongated morphol-
ogy associated with hBMSCs48 on all cement formulations.
Proliferation was quantiﬁed using a PicoGreen assay.
There was a general trend toward increasing cell number
for all cements, with a signiﬁcant increase in cell number
measured between days 7 and 14. However, no signiﬁcant
variation was seen between day 1 and day 7 for any of the
cements, with the exception of VP-PMMA, where the
increase in dsDNA concentration was more gradual with sig-
niﬁcant increases seen between each of the three time
points. It is unclear why proliferation seems to be delayed
for the CPC systems compared with the VP-PMMA, although
it may be as a result of the increased differentiation, which
is known to result in the down-regulation of proliferation.49
It has also been suggested that the initial seeding of cells
onto CPCs can result in altered adhesion characteristics,
thus affecting cell growth.50 It is surmised that this change
in adhesion characteristics is partially due to the acidiﬁca-
tion of the culture media. Further, the reduction of available
divalent cations as a result of calcium-deﬁcient materials
has also been shown to compromise cell adherence,51 which
may also explain the observed delay in proliferation. Despite
this, cells generally proliferated equally well on all of the
cement types.
In addition to proliferation, the degree of osteogenic dif-
ferentiation was also assessed by quantifying ALP activity. Dif-
ferentiation was observed on all cement types and was shown
to increase with time. Increased osteogenic potential was dis-
played by cells cultured on all of the CPC systems when com-
pared with VP-PMMA, a ﬁnding which was expected due to
the lack of bioactivity associated with PMMA.
It is possible that factors other than cement composition
are responsible for these differences. However, identifying
such factors remains difﬁcult because the mechanism
underlying osteoinduction by biomaterials is not fully
understood.52 Barradas et al.52 have summarized some fac-
tors involved in osteoinduction; these include, in addition to
chemical composition, implant geometry, porosity, surface
roughness, and speciﬁc surface area. It has also been shown
that nanopatterns on the surface of PMMA can induce mes-
enchymal stem cells to differentiate along the osteogenic lin-
eage, even in the absence of osteogenic supplements.53
The differing levels of ALP activity displayed by BC-CPC
compared with Merck-CPC and a-TCP-CPC may be a result
of the differences in surface topography. The surface rough-
ness of BC-CPC was signiﬁcantly higher than both that of
MC-CPC and a-TCP-CPC.43 The effect of topography on cell
behavior is complex and needs to be considered on multiple
scales,54 with topography on the nanoscale shown to affect
differentiation.53 However, it has been suggested that differ-
entiation can be delayed by rougher surfaces,48 which is in
agreement with the ﬁndings reported in this study.
Cells cultured on BC-CPC had lower osteogenic capacity
compared with those on MC-CPC, and this may be due to
differences in the collagens used. To the best of the authors’
knowledge, this work is the ﬁrst investigation comparing
the biocompatibility of collagen from C. reniformis with that
derived from bovine Achilles tendon. Indeed, few studies
have compared the biocompatibility of marine collagens
with that of mammals. However, in a study comparing scaf-
folds of jellyﬁsh collagen with those produced from type I
collagen from calf skin, the jellyﬁsh collagen did not induce
a signiﬁcant cytotoxic effect on human ﬁbroblasts and sup-
ported higher cell viability compared with the bovine colla-
gen.14 Although no signiﬁcant difference in cytotoxicity was
observed between the marine and bovine collagens eval-
uated herein, the work involving the jellyﬁsh collagen does
highlight the potential for interspeciﬁc differences in the in
vitro behavior of collagens.
In a study by Nagai et al.,55 human periodontal ligament
ﬁbroblasts (HPdLFs) were cultured on cross-linked salmon
collagen gel and porcine collagen gel. HPdLF growth rate
was shown to be faster on the salmon gel when compared
with that on the porcine gel. Also, HPdLFs cultured on the
salmon gel displayed a higher level of ALP activity than that
of those cultured on the porcine gel, as well as an increased
messenger RNA expression of type I collagen and osteocal-
cin. The use of collagen gels rather than ﬁbers coupled with
the fact that different species were used limits the compari-
sons that can be made between the study by Nagai et al.
and the ﬁndings presented in this study. Notwithstanding
this fact, it is interesting to note that ALP activity was
higher for the ﬁsh-derived collagen gel in comparison with
the mammalian-derived collagen gel. This is in agreement
with the ﬁnding that ALP activity was higher in MC-CPC
compared with BC-CPC; although it can only be speculated
that these similarities are a result of the aquatic source of
the collagens involved.
CONCLUSIONS
This study demonstrated that all of the CPCs considered
supported cell attachment and improved osteogenicity when
compared with VP-PMMA.
a-TCP-CPC displayed comparable in vitro biological prop-
erties with Merck-CPC. Also, despite demonstrating a signiﬁ-
cant, but clinically irrelevant increase in cytotoxicity, the
incorporation of 1 wt % collagen derived from C. reniformis
had an insigniﬁcant inﬂuence on the in vitro biological prop-
erties of a-TCP-CPC. This ﬁnding, coupled with the knowl-
edge that incorporation of marine collagen in this way
improves the physical properties of a-TCP-CPC, suggests
that it may be a suitable alternative to some of the clinically
used bone cements in application such as vertebroplasty,
where mechanical stability is essential.
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